Back to search results

Study of Arlocabtagene Autoleucel Combinations for Relapsed or Refractory Multiple Myeloma

This study is looking at new combinations of treatments for people with multiple myeloma that has come back or not responded to previous treatments (relapsed and/or refractory multiple myeloma). Researchers want to find a safe and effective dose of arlocabtagene autoleucel (BMS-986393) when given with other drugs like alnuctamab, mezigdomide, iberdomide, and elranatamab. The main goal is to see how many side effects, including serious ones, occur over two years. You might be able to join if you are 18 or older and have a history of multiple myeloma that has relapsed or is refractory, with specific prior treatments. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 187 participants. It is testing different drug combinations.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for side effects for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
PHASE1Ages 18+InterventionalTreatment
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
~187 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:BMS-986393AlnuctamabMezigdomideIberdomideElranatamabDexamethasone

At a glance

Recruiting sites
17 of 19 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events (AEs)
Measured over Up to 2 years
+5 more outcomes measured

Conditions

Multiple Myeloma

Explore related trials

Multiple Myeloma

Where it's being run

19 sites across 15 states
New York4
Massachusetts2
Alabama1
Arizona1
California1
Florida1
Georgia1
Minnesota1

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E).
Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
Eastern Cooperative Oncology Group performance status of 0-1.
Adherence to contraception requirements.

Exclusion

Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2).

What this trial measures

  • Incidence of adverse events (AEs)Up to 2 years
  • Incidence of serious adverse events (SAEs)Up to 2 years
  • Incidence of adverse events of special interest (AESI)Up to 2 years
  • Incidence of AEs leading to discontinuationUp to 2 years
  • Number of DeathsUp to 2 years
  • Establish recommended Phase 2 dose (RP2D)Up to 2 years